By Joseph Walker
Biogen shares fell, after the biotechnology company forecast lower-than-expected revenue and profit for this year, saying multiple-sclerosis drug sales will decline further and will only be partially offset by new products.
Competition, including from cheap generics, has weighed on Biogen's costly MS drugs. Meanwhile, growth from new drugs like rare-disease treatment Skyclarys has been slower than expected.
In the most-recent quarter, Skyclarys sales totaled $102 million, or $10 million less than forecast by analysts polled by FactSet.
"Biogen's business outlook is unimpressive and unlikely to change any time soon," Cantor analyst Eric Schmidt said in a note to clients.
Shares traded about 7% lower on Wednesday morning.
-- For 2025, Biogen expects adjusted earnings of $15.25 to $16.25 a share. That compares to the $16.33 forecast by analysts.
-- Bigoen expects "a mid-single digit percentage" decline in full-year sales. That works out to a couple hundred million dollars less than the $9.4 billion analysts predicted.
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
February 12, 2025 10:22 ET (15:22 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。